Blood test predicts which patients with lung cancer will benefit from newly approved immunotherapy drug

TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer

- Study Results Support the use of TellDx to Personalize Cancer Care Management - -- Clinical study published in Cancer Discovery -- ANDOVER, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE)...

Blood test predicts which patients with lung cancer will benefit from newly approved immunotherapy drug

A team led by investigators at the Mass General Brigham Cancer Institute has discovered that a particular marker on tumor cells circulating in the blood indicates whether a patient with lung cancer will experience a lasting response to a newly approved immunotherapy called tarlatamab.

A simple blood test may predict lung cancer treatment outcomes

Researchers at the Mass General Brigham Cancer Institute have made an exciting discovery that could change how lung cancer is treated. They found that a specific signal, or marker, on cancer cells found in a patient’s blood can help predict whether a new drug called tarlatamab will work for them. This test could give doctors […] The post A simple blood test may predict lung cancer treatment outcomes appeared first on Knowridge Science Report.

Blood Test Predicts Response to Newly Approved SCLC Immunotherapy

A research team led by investigators at the Mass General Brigham Cancer Institute has developed a liquid biopsy test that can accurately stratify patients with small cell lung cancer (SCLC) based on their likelihood to positively respond to Amgen’s Imdelltra (tarlatamab). These findings, published today in Cancer Discovery, could represent a major step forward in diagnosis and treatment for a form of lung cancer with limited treatment options.  …